story of the week
Luspatercept vs Epoetin Alfa for Erythropoiesis-Stimulating Agent–Naïve, Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Lancet Haematol 2024 Jul 19;[EPub Ahead of Print], MGD Porta, G Garcia-Manero, V Santini, AM Zeidan, RS Komrokji, J Shortt, D Valcárcel, A Jonasova, S Dimicoli-Salazar, IS Tiong, CC Lin, J Li, J Zhang, R Pilot, S Kreitz, V Pozharskaya, KL Keeperman, S Rose, T Prebet, Y Lai, A Degulys, S Paolini, T Cluzeau, P Fenaux, U PlatzbeckerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.